Collectively, these findings demonstrate that PD-1 blockade with InVivoMab, particularly in combination with RT, promotes robust T-cell infiltration and functional activation within the tumor microenvironment, thereby enhancing antitumor immunity (Figure 3). The gene discussed is PDCD1; the disease is neoplasm.